Read the full release \u2192<\/a><\/p>\nNews provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"SUMMIT, N.J., June 24, 2026 \/PRNewswire\/ — Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor\u00ae;\u2026<\/p>\n","protected":false},"author":14,"featured_media":1931,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1929","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-well-being"],"yoast_head":"\n
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"SUMMIT, N.J., June 24, 2026 \/PRNewswire\/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor\u00ae;\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T18:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients\",\"datePublished\":\"2026-06-24T18:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/\"},\"wordCount\":60,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png\",\"articleSection\":[\"Community Well-Being\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/\",\"name\":\"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png\",\"datePublished\":\"2026-06-24T18:50:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte","og_description":"SUMMIT, N.J., June 24, 2026 \/PRNewswire\/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor\u00ae;\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-24T18:50:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients","datePublished":"2026-06-24T18:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/"},"wordCount":60,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png","articleSection":["Community Well-Being"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/","name":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png","datePublished":"2026-06-24T18:50:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients-ai.png","width":1536,"height":1024,"caption":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/vascarta-announces-phase-i-results-of-vas-101-administered-sublingually-in-sickle-cell-disease-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/1929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=1929"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/1929\/revisions"}],"predecessor-version":[{"id":9523,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/1929\/revisions\/9523"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/1931"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=1929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=1929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=1929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}